Background: To systematically review the epidemiologic relationship between periodontitis and type 2 diabetes mellitus (T2DM). Methods: Four electronic databases were searched up until December 2018. The manual search included the reference lists of the included studies and relevant journals. Observational studies evaluating the relationship between T2DM and periodontitis were included. Meta-analyses were conducted using STATA. Results: A total of 53 observational studies were included. The Adjusted T2DM prevalence was significantly higher in periodontitis patients (OR = 4.04, p = 0.000), and vice versa (OR = 1.58, p = 0.000). T2DM patients had significantly worse periodontal status, as reflected in a 0.61 mm deeper periodontal pocket, a 0.89 mm higher attachment loss and approximately 2 more lost teeth (all p = 0.000), than those without T2DM. The results of the cohort studies found that T2DM could elevate the risk of developing periodontitis by 34% (p = 0.002). The glycemic control of T2DM patients might result in different periodontitis outcomes. Severe periodontitis increased the incidence of T2DM by 53% (p = 0.000), and this result was stable. In contrast, the impact of mild periodontitis on T2DM incidence (RR = 1.28, p = 0.007) was less robust. Conclusions: There is an evident bidirectional relationship between T2DM and periodontitis. Further well-designed cohort studies are needed to confirm this finding. Our results suggest that both dentists and physicians need to be aware of the strong connection between periodontitis and T2DM. Controlling these two diseases might help prevent each other's incidence.

No abstract

Objective:Aimed to evaluate the effect and response from the adjuvant chemotherapy for locally advanced oral squamous cell carcinoma. Methods: Retrospectively collected 46 patients with local late oral squamous cell carcinoma admitted from 2017 to 2021. The patients were treated with TPF induction chemotherapy. All patients completed at least 2 cycle of TPF (PF) regimen (75 mg / m2 of docetaxel on day 1 + 75 mg / M2 of cisplatin on day 1 + 750 mg / m2 of 5-fluorouracil on days 1 ~ 5, one cycle every 21 days), The primary end-points were overall response rate, safety of therapy and overall survival were evaluated. Results: After two cycles of TPF treatment, patients continued receiving surgery followed by radiotherapy or chemotherapy, include 5 patients were received PF. The complete remission rate was 6.25% (2/32), and the objective remission rate was 71.88% (23/32). Most of the adverse factors of chemotherapy response are alleviated. The median follow-up time was 26 months, and the median OS was 25.51 ± 3.81 months. Conclusion: Neoadjuvant chemotherapy, such as TPF or PF, plays an important role in the comprehensive treatment of advanced OSCC and postoperative assessments of white blood cell can provide high-quality prognostic information.